The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Supramolecular “Trojan Horse” for Nuclear Delivery of Dual Anticancer Drugs
Abstract
Nuclear delivery and accumulation are very important for many anticancer drugs that interact with DNA or its associated enzymes in the nucleus. However, it is very difficult for neutrally and negatively charged anticancer drugs such as 10-hydroxycamptothecine (HCPT). Here we report a simple strategy to construct supramolecular nanomedicines for nuclear delivery of dual synergistic anticancer drugs. Our strategy utilizes the coassembly of a negatively charged HCPT-peptide amphiphile and the positively charged cisplatin. The resulting nanomaterials behave as the "Trojan Horse" that transported soldiers (anticancer drugs) across the walls of the castle (cell and nucleus membranes). Therefore, they show improved inhibition capacity to cancer cells including the drug resistant cancer cell and promote the synergistic tumor suppression property in vivo. We envision that our strategy of constructing nanomaterials by metal chelation would offer new opportunities to develop nanomedicines for combination chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Casting Metal Nanowires Within Discrete Self-Assembled Peptide Nanotubes
Reches, M., & Gazit, E. (2003) · Science · doi:10.1126/science.1082387 · Cited by 2,530
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
DNA and its associated processes as targets for cancer therapy
Hurley, L. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc749 · Cited by 1,349
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Huang, P., Wang, D., Su, Y., Huang, W., Zhou, Y., Cui, D., Zhu, X., & Yan, D. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505212y · Cited by 716
Cited by
Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials
Chen, W., Luo, G., & Zhang, X. (2019) · Advanced Materials · doi:10.1002/adma.201802725 · Cited by 373
Hua, X.-W., Bao, Y.-W., & Wu, F.-G. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b19549 · Cited by 339
Metadata
- Authors
- Cai, Y., Shen, H., Zhan, J., Lin, M., Dai, L., Ren, C., Shi, Y., Liu, J., Gao, J., & Yang, Z.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-02-14
- Volume
- 139
- Issue
- 8
- Pages
- 2876-2879
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W2588384666
- Cited by
- 293
- References
- 30
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Supramolecular “Trojan Horse” for Nuclear Delivery of Dual Anticancer Drugs. https://app.cochat.ai/papers/10.1021/jacs.6b12322
- The paper
- Cai, Y., Shen, H., Zhan, J., Lin, M., Dai, L., Ren, C., Shi, Y., Liu, J., Gao, J., & Yang, Z. (2017). Supramolecular “Trojan Horse” for Nuclear Delivery of Dual Anticancer Drugs. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.6b12322
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
